Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isotretinoin effects on neuropeptides in rosacea
NCT06873087Phase 4Completed
- Sponsor
- Istanbul Education Research Hospital
- Start
- Sep 2023
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of isotretinoin in papulopustular rosacea, sponsored by Istanbul Education Research Hospital. Primary endpoints: Change in Pituitary Adenylate Cyclase-Activating Polypeptide Levels at 3 months, Change in Calcitonin Gene-Related Peptide Levels at 3 months and 1 more. Started Sep 2023; status: completed.
02
Drugs
isotretinoin
03
Conditions
papulopustular rosacea
Beyond the preview
Go deeper on NCT06873087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06873087.